antibody

Sheep anti-human Prekallikrein (PK), Peroxidase Conjugated Affinity Purified IgG

MBS512193

0.1 mg

340 USD

polyclonal

sheep

HRP

Antibody

Sheep anti-human Prekallikrein (PK), Peroxidase Conjugated Affinity Purified IgG

[Prekallikrein]

[Prekallikrein, human]

Polyclonal

Sheep

Prior to conjugation, this antibody was specific for prekallikrein as demonstrated by immunoelectrophoresis and ELISA.

Affinity purified, peroxidase conj. IgG. Vial containing ml of affinity purified IgG conjugated to horseradish peroxidase (HRP) through carbohydrate groups. Total protein is 0.1 mg.

APIgG-HRP conjugate as a clear, slightly red-brown liquid.

APIgG-HRP concentration is 1 mg/ml, determined by absorbance using an extinction coefficient (E 1% 280) of 14.

Store between -10 and -20 degree C. Product will become viscous but will not freeze. Avoid storage in frost-free freezers. Keep vial tightly capped. Allow product to warm to room temperature and gently mix before use. Avoid exposure to sodium azide as this is an inhibitor of peroxidase activity.

Suitable as a source of peroxidase labelled antibodies to prekallikrein.

Immunogen: Human active site-blocked kallikrein prepared from plasma.

Buffer: A buffered stabilizer solution containing 50% (v/v) glycerol. Rz Ratio (Reinheitszahl, A403/A280): 0.42 as determined spectrophotometrically

Vial containing 0.1ml of affinity purified IgG conjugated to horseradish peroxidase (HRP) through carbohydrate groups. Total protein is 0.1mg. Prekallikrein (PK), previously known as Fletcher Factor, is a single chain glycoprotein produced in the liver. The plasma concentration of PK is 50 ug/ml (550 nM), approximately 75% of which circulates in complex with high molecular weight kininogen (HK) and the remainder as free PK. Plasma PK is heterogeneous in both mass and charge due to variable degrees of glycosylation. Approximately 90% of plasma PK has an apparent molecular weight of 88 kDa as determined by SDS-PAGE and the remaining 10% has an apparent mass of 85 kDa. The catalytic site resides in the light chain. The heavy chain of PK contains four appledomain structures similar to those found in FXI and these are required for binding of PK to HK. PK is the zymogen form of the enzyme kallikrein, which is involved in the proteolysis of kininogens with subsequent release of bradykinin, a potent vasodilator. PK participates in the contact phase of coagulation as a substrate for surface-bound activated factor XII (FXIIa) in the presence of the cofactor HK. As PK and factor XI (FXI) both circulate in complex with HK, both are localized to activating surfaces through their respective binding to HK. Limited proteolysis of PK by FXIIa generates kallikrein, a two-chain serine protease that initiates the reciprocal activation of PK and FXI. Kallikrein activity in plasma is regulated predominantly by C1- Inhibitor and alpha2macroglobulin, with relatively minor contributions by Protein C Inhibitor, alpha2antiplasmin, and antithrombin1-3.

1. Coleman RW, Schmaier AH; Contact System: A Vascular Biology Modulator With Anticoagulant, Profibrinolytic, Antiadhesive and Proinflammatory Attributes. Blood 90, pp 3819-3843, 1997. 2. DeLa Cadena R, Watchtfogel YT, Colman RW, in Hemostasis and Thrombosis, 3rd Edition, eds. RW Colman, J Hirsh, VJ Marder and EW Salzman, pp. 219-240, J.B. Lippincott Co., Philadelphia, 1994. 3. Hojima Y, Pierce JV, Pisano JJ; Purification and Characterization of Multiple Forms of Human Plasma Prekallikrein. JBC 260, pp 400-406, 1985.

0.1 mg

340 USD